Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

OncoAlert and ecancer - ESMO 2021 Day 4

ESMO 2021

17 - 21 Sep 2021

Published: 20 Sep 2021

Views: 845

Rating:

Save

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

Dr Gil Morgan from OncoAlert gives his insights on what to look out for from Day 4 of ESMO 2021.

Dr Morgan mentions results from studies including STAMPEDE, CheckMate 649, TULIP, MONALEESA-2 and KEYNOTE-355.

You can watch Dr Morgan's previous roundup here.

Follow Dr Morgan on twitter: @OncoAlert

Follow ecancer on twitter: @ecancer

Search and follow #OncoAlertTopTweet to stay up to date.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for...

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal...

Dr Ronan Kelly - Baylor University Medical Center, Texas, USA

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis ( Dr Ronan Kelly - Baylor University Medical Center, Texas, USA )

Lenvatinib plus pembrolizumab versus standard of care for previously treated...

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

More from ecancer